Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis
29 Ιανουαρίου 2024
Colapietro Jan. 2024:https://doi.org/10.1016/j.jhep.2023.09.010 Πατώντας ΕΔΩ μπορείτε να δείτε το άρθρο
Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving b-blockers+ligation to prevent re-bleeding
22 Ιανουαρίου 2024
Lorenz Balcar, Mattias Mandorfer, Virginia Hernández-Gea, ., Vincenzo La Mura, Jaime Bosch, Juan Carlos García-Pagán Journal of Hepatology, January 2024 Volume 80 Issue 1p1-172, e1-e36
Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis
16 Ιανουαρίου 2024
John BV, Dang Y, Kaplan DE, Bastaich DR, Chao HH, Dahman B, et al. Clin Gastroenterol Hepatol Published: December 05, 2023 DOI:https://doi.org/10.1016/j.cgh.2023.11.020 Πατώντας ΕΔΩ μπορείτε
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
12 Δεκεμβρίου 2023
Thit M Kronborg , Robert Schierwagen, Kajetan Trošt, Qian Gao, Thomas Moritz, Flemming Bendtsen , Rasmus H Gantzel, Mette L Andersen, Ane S Teisner, Henning Grønbæk, Lise Hobolth , Søren Møller, Jonel Trebicka , Nina Kimer Hepatology Communications 7(12):e0332, December 2023. | DOI: 10.1097/HC9.0000000000000332 Πατώντας ΕΔΩ
Αξιολόγηση του κινδύνου ανάπτυξης ηπατοκυτταρικού καρκίνου σε ασθενείς με χρόνια ηπατίτιδα C
4 Δεκεμβρίου 2023
Lu M, Salgia R, Li J, et al. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2023;30:746–755. DOI:
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
23 Νοεμβρίου 2023
Kowdley et al NEJM 2023. Nov 13. doi: 10.1056/NEJMoa2306185 Πατώντας ΕΔΩ μπορείτε να δείτε το άρθρο
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase
8 Νοεμβρίου 2023
Huang D, Tran A, Yeh ML, Yasuda S, Tsai PC, Pei-Chien H, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
30 Οκτωβρίου 2023
Shukui Q., Minshan C., Ann-Lii C. et al. for the IMbrave050 investigators The Lancet, October 2023 (published online first) doi: (https://doi.org/10.1016/S0140-6736(23)01796-8) Δείτε ΕΔΩ το άρθρο.
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement
18 Οκτωβρίου 2023
Transplant International 36:11729. DOI: 10.3389/ti.2023.11729 https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11729/full Δείτε ΕΔΩ το άρθρο.
Τυχαιοποιημένη, ελεγχόμενη δοκιμή του αναλόγου FGF21 Pegozafermin στη NASH
16 Οκτωβρίου 2023
Rohit Loomba, M.D., M.H.Sc., Arun J. Sanyal, M.D., Kris V. Kowdley, M.D., et al N Engl J Med 2023; 389:998-1008 DOI: 10.1056/NEJMoa2304286 Δείτε ΕΔΩ το